The Sun Pharma stock hit its 52-week high earlier this week on strong domestic growth expectations and improved outlook for the US market, following the clearance for its Halol manufacturing plant in Gujarat. The stock is up almost 20 per cent in less than a month after the company posted better-than-expected June-quarter earnings.
Analysts at Credit Suisse have upgraded the stock recently as they believe upside from an acne treatment drug could lead to a re-rating. The key near-term trigger is the company's specialty pipeline. In addition to the recent launch of Yonsa ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Note: Subscription will be auto renewed, you may cancel any time in the future without any questions asked.
What you get?
ON BUSINESS STANDARD DIGITAL
- Unlimited access to all the content on any device through browser or app.
- Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
- Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
- Track the industry of your choice with a daily newsletter specific to that industry.
- Stay on top of your investments. Track stock prices in your portfolio.
- 18 years of archival data.
- Requires you to share personal information like date of birth, income, location amongst other fields. This information alongwith your contact information will be shared with the partners associated with this program, who contribute towards subsidizing the offer. By subscribing to this product you acknowledge and accept that our Partners may choose to contact you with offers of their products and services.
- This is an optional offer - Not comfortable with sharing personal data - please opt for the full price offer which requires you to share minimal information